New Hampshire Patent of the Month – July 2024
Adimab, LLC, a biologics company based in New Hampshire, is revolutionizing antibody discovery with its newly patented synthetic libraries. Traditional methods of antibody development often rely on natural sources, limiting diversity and sometimes necessitating extensive humanization for therapeutic use. Adimab’s breakthrough lies in their library of synthetic polynucleotides encoding light chain variable regions, meticulously designed to mimic the diversity found in the human immune system.
This library comprises sequences highly similar to known human antibody sequences, ensuring minimal immunogenicity and maximizing affinity for human antigens. By varying key positions within specific sequences like VK1-05, VK1-12, and others, Adimab enhances the library’s capability to recognize a broad spectrum of targets. These variations are strategically chosen based on the most frequent amino acids found in natural antibodies, optimizing the likelihood of successful antigen binding.
The method of producing antibodies from this library is straightforward yet powerful: the library is expressed in host cells, typically yeast, which are adept at protein expression. This approach not only streamlines the discovery process but also enhances the probability of identifying antibodies with desired properties for therapeutic or diagnostic applications.
Adimab’s libraries also address critical limitations of existing methods by offering unparalleled diversity without introducing non-human sequences that could trigger immune responses. This advancement not only accelerates antibody discovery but also ensures that the resulting antibodies are safer and more effective for human use.
Adimab’s synthetic antibody libraries combine computational design with extensive biological data to create libraries that mirror and expand upon nature’s own immune repertoire. These libraries promise to significantly impact fields ranging from drug development to diagnostics, offering researchers and clinicians a powerful toolset for combating disease with precision and efficacy.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
